alk1 inhibitor Search Results


ml 347  (Bio-Techne corporation)
93
Bio-Techne corporation ml 347
Ml 347, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ml 347/product/Bio-Techne corporation
Average 93 stars, based on 1 article reviews
ml 347 - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier
bone morphogenetic protein receptor inhibitor k02288  (Biomol GmbH)
90
Biomol GmbH bone morphogenetic protein receptor inhibitor k02288
Growth factors were not responsible for the stimulating effect of MSC-CM on Na + transport. FDLE cells were subjected to MSC-CM or control medium for 24 h with or without the respective growth receptor inhibitor. Data are displayed as boxes and whiskers with the 10–90 percentiles, mean (+), and median (horizontal line). Statistical differences among groups were analyzed with an ANOVA and Tukey’s post hoc test. a Inhibition of VEGF-R with Axitinib ( n = 19–23, 2 IE; *** p < 0.001), b <t>BMP-R</t> with <t>K02288</t> ( n = 22–24, 2 IE; *** p < 0.001), and c PDGF-R with AG-1296 ( n = 18–22, 2 IE; *** p < 0.001) did not affect Na + transport in MSC-CM-treated and control cells. d The EGF-R inhibitor AG-1478 ( n = 19–24, 2 IE; *** p < 0.001), e the TGF-β-R inhibitor SB431542 ( n = 21–24, 2 IE; * p < 0.05; *** p < 0.001), f the FGF-R inhibitor FIIN-2 ( n = 16–24, 2 IE; * p < 0.05; ** p < 0.01; *** p < 0.001), and g the HGF-R (c-met) inhibitor PHA665752 ( n = 64–67, 6 IE; ** p < 0.01; *** p < 0.001) reduced ∆ I amil in control and MSC-CM-treated cells. Inhibition did not prevent the stimulating effect of MSC-CM. □ control, ■ MSC-CM
Bone Morphogenetic Protein Receptor Inhibitor K02288, supplied by Biomol GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bone morphogenetic protein receptor inhibitor k02288/product/Biomol GmbH
Average 90 stars, based on 1 article reviews
bone morphogenetic protein receptor inhibitor k02288 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


Growth factors were not responsible for the stimulating effect of MSC-CM on Na + transport. FDLE cells were subjected to MSC-CM or control medium for 24 h with or without the respective growth receptor inhibitor. Data are displayed as boxes and whiskers with the 10–90 percentiles, mean (+), and median (horizontal line). Statistical differences among groups were analyzed with an ANOVA and Tukey’s post hoc test. a Inhibition of VEGF-R with Axitinib ( n = 19–23, 2 IE; *** p < 0.001), b BMP-R with K02288 ( n = 22–24, 2 IE; *** p < 0.001), and c PDGF-R with AG-1296 ( n = 18–22, 2 IE; *** p < 0.001) did not affect Na + transport in MSC-CM-treated and control cells. d The EGF-R inhibitor AG-1478 ( n = 19–24, 2 IE; *** p < 0.001), e the TGF-β-R inhibitor SB431542 ( n = 21–24, 2 IE; * p < 0.05; *** p < 0.001), f the FGF-R inhibitor FIIN-2 ( n = 16–24, 2 IE; * p < 0.05; ** p < 0.01; *** p < 0.001), and g the HGF-R (c-met) inhibitor PHA665752 ( n = 64–67, 6 IE; ** p < 0.01; *** p < 0.001) reduced ∆ I amil in control and MSC-CM-treated cells. Inhibition did not prevent the stimulating effect of MSC-CM. □ control, ■ MSC-CM

Journal: Stem Cell Research & Therapy

Article Title: Paracrine stimulation of perinatal lung functional and structural maturation by mesenchymal stem cells

doi: 10.1186/s13287-020-02028-4

Figure Lengend Snippet: Growth factors were not responsible for the stimulating effect of MSC-CM on Na + transport. FDLE cells were subjected to MSC-CM or control medium for 24 h with or without the respective growth receptor inhibitor. Data are displayed as boxes and whiskers with the 10–90 percentiles, mean (+), and median (horizontal line). Statistical differences among groups were analyzed with an ANOVA and Tukey’s post hoc test. a Inhibition of VEGF-R with Axitinib ( n = 19–23, 2 IE; *** p < 0.001), b BMP-R with K02288 ( n = 22–24, 2 IE; *** p < 0.001), and c PDGF-R with AG-1296 ( n = 18–22, 2 IE; *** p < 0.001) did not affect Na + transport in MSC-CM-treated and control cells. d The EGF-R inhibitor AG-1478 ( n = 19–24, 2 IE; *** p < 0.001), e the TGF-β-R inhibitor SB431542 ( n = 21–24, 2 IE; * p < 0.05; *** p < 0.001), f the FGF-R inhibitor FIIN-2 ( n = 16–24, 2 IE; * p < 0.05; ** p < 0.01; *** p < 0.001), and g the HGF-R (c-met) inhibitor PHA665752 ( n = 64–67, 6 IE; ** p < 0.01; *** p < 0.001) reduced ∆ I amil in control and MSC-CM-treated cells. Inhibition did not prevent the stimulating effect of MSC-CM. □ control, ■ MSC-CM

Article Snippet: The inhibitors of the VEGF receptor (Axitinib, 10 μM), the bone morphogenetic protein receptor (BMP-R; K02288, 1 μM), the platelet-derived growth factor receptor (PDGF-R; AG-1296, 10 μM), the EGF receptor (EGF-R; AG-1478, 1 μM), the transforming growth factor β receptor (TGF-β-R; SB431542, 1 μM), the FGF receptor (FGF-R; FIIN-2, 1 μM), and the HGF receptor c-met (PHA665752, 1 μM) were purchased from Biomol (Hamburg, Germany).

Techniques: Control, Inhibition